Navigation Links
Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
Date:6/6/2011

ourse of disease progression.  In particular, drugs which are well tolerated and which do not limit subsequent treatment options because of bone marrow or other organ toxicity are demanded.  In the aggressive lymphomas, it is our belief that the need exists for agents that can combine with standard therapies to improve cure rate, and for agents that are effective in patients that fail potentially curative therapy.

A typical treatment of NHL includes a diverse combination of chemotherapies in addition to rituximab or other monoclonal antibodies. Such treatments, particularly in combination, can exceed a cost of $100,000 for a 12-month treatment period.

In the major pharmaceutical markets in the US, Europe and Japan, Decision Resources, Inc. estimates the following for 2011: There are 305,440 prevalent cases living with DLBCL, with 50,180 patients estimated to be in the first line setting and 34,320 patients estimated to be in the relapsed/refractory setting. CLL/SLL constitutes about one-third of the B-cell malignancy population. There are 172,630 prevalent cases living with CLL, with 39,390 patients estimated to be in the first line setting and 33,550 patients estimated to be in the relapsed/refractory CLL setting. Follicular lymphoma (FL) constitutes about 20% of the B-cell malignancy population and is considered an indolent, yet incurable, disease. There are 136,450 prevalent cases living with FL, with 21,050 patients estimated to be in the first line setting and 14,270 patients estimated to be in the relapsed/refractory setting.  MCL, generally an aggressive form of lymphoma, comprises approximately 5% of the newly diagnosed B-cell malignancies. There are 32,180 prevalent cases living with MCL, with 5,300 patients estimated to be in the first line setting and 4,140 patients estimated to be in the relapsed/refractory setting.

The prevalence of NHL is large and according to the Leukemia & Lymphoma Society, in 2010 there we
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... ORANGEBURG, N.Y. , June 2, 2015 /PRNewswire/ ... products and solutions, today announced a series of ... customers about strategies to reduce the threat of ... with the US Centers for Disease Control and ... House,s National Strategy to Combat Antibiotic-Resistant Bacteria. ...
(Date:6/2/2015)... 02, 2015 Research and Markets ( ... PharmaBiotech,s new report "Drug Delivery in Central ... to their offering. The delivery ... a challenge in the treatment of neurological disorders. ... or administered systematically (e.g., by intravenous injection) for ...
(Date:6/2/2015)... June 2, 2015 The Canadian Society for Vascular ... tests, treatments or procedures that are commonly ordered ... part of Choosing Wisely Canada.  The list identifies ... conversations between patients and physicians about what care ... for Vascular Surgery,s list identified the following five ...
Breaking Medicine Technology:PDI Partners with White House and Centers for Disease Control and Prevention (CDC) to Combat Antimicrobial Resistance 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 3As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 2As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 3As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 4
... July 28, 2011 Roka Bioscience, Inc. announced today ... equity financing, raising $20 million in new capital. The ... since the company,s formation in September 2009. The investor ... Advisors, New Enterprise Associates, Inc., TPG Biotech and Gen-Probe ...
... spending growth slowed from an estimated 5.3 percent in ... data released today by the Centers for Medicare and ... Researchers credit the slowdown in spending growth to pharmacy ... toward lower cost generic drugs. Pharmaceutical Care Management ...
Cached Medicine Technology:Roka Bioscience Completes $20 Million Series C Financing 2PCMA: Study Credits PBM Tools with Reducing Prescription Drug Spending Growth 2
(Date:6/2/2015)... UCLA Health and Exer have completed negotiations and ... urgent care services in Los Angeles County. The ... California Board of Regents and the Exer Board of ... purchase a minority share of four existing Exer urgent ... Northridge and creates opportunity to grow and develop new, ...
(Date:6/2/2015)... New Jersey (PRWEB) June 02, 2015 ... (Horizon BCBSNJ) announced today that its Walking and Wellness ... Classic Presented by Acer, has raised another $3,000 for ... Natalie Gulbis undertook the challenge, recording 32,000 steps on ... at Stockton Seaview Hotel & Golf Club in Galloway ...
(Date:6/2/2015)... June 02, 2015 Bitscape Infotech today ... 2015 Microsoft Worldwide Small and Midsized Cloud Solutions Award. ... top Microsoft partners for demonstrating excellence in innovation and ... , “This comes as no surprise to us as ... year consecutively at worldwide level by Microsoft. We will ...
(Date:6/2/2015)... Radaris ” was featured on NewsWatch as part of its ... coolest applications on the market for iOS, Android, and Windows. ... the app review and shared with viewers can help users ... According to Psychology Today, humans are a curious species by ... is a part of human development. People are using the ...
(Date:6/2/2015)... 02, 2015 Tronics, a designer and ... growth strategy to benefit from the significant growth expected ... May 2015 Status of the MEMS Industry report, we ... reach $6.6B in 2020,” says Frederic Breussin, Business Unit ... , The analyst adds that “although the BioMEMS market ...
Breaking Medicine News(10 mins):Health News:UCLA Health Partners With Exer - More Than Urgent Care 2Health News:LPGA’s Natalie Gulbis Raises an Additional $3,000 for the Boys & Girls Club of Atlantic City Through Horizon BCBSNJ’s Walking and Wellness Challenge 2Health News:Bitscape Infotech recognized as finalist for 2015 Microsoft Worldwide small & midsized cloud solutions award. 2Health News:Bitscape Infotech recognized as finalist for 2015 Microsoft Worldwide small & midsized cloud solutions award. 3Health News:A Comprehensive People Search Application Was Featured on NewsWatch Television 2Health News:Tronics Aims to Benefit from Major Growth of Sensors and Related Technologies for Healthcare Applications 2
... finds city-dwelling females have more dense breasts, , , MONDAY, Nov. ... appear to have more dense breast tissue than their suburban ... potentially important because women with more dense breasts have a ... compared rural women from Greece to suburban and urban women ...
... a smoking gun, but its smoking-related, and its there ... deep in the lungs, caused by secondhand cigarette smoke. ... to nonsmokers that was long suspected, but not previously ... suggest that their findings may strengthen public health efforts ...
... For the first time, researchers have identified structural ... , The results of the study, conducted by ... in Charlottesville and The Childrens Hospital of Philadelphia in ... the Radiological Society of North America (RSNA). , Its ...
... clinical professor of neurology at Boston University School of ... Study, was recently awarded the Stroke Council Award from ... at the AHAs recent Scientific Sessions meeting in Orlando, ... encourages those who actively work to integrate stroke and ...
... at Yale and Cornell have created a modified chemotherapy ... of brain tumors by adding a water-soluble polymer ... the November-December issue of Bioconjugate Chemistry. , This approach ... than a centimeter, which may be sufficient to prevent ...
... Imaging, a,wholly owned subsidiary of Mercury Computer Systems, ... Siemens Medical Solutions to deliver advanced,3D visualization and ... Siemens will integrate Visage Imaging,s advanced 3D ... This unique thin client-based,image distribution solution will be ...
Cached Medicine News:Health News:Urban Women May Have Greater Breast Cancer Risk 2Health News:Urban Women May Have Greater Breast Cancer Risk 3Health News:Secondhand smoke damages lungs, MRIs show 2Health News:Novel MRI technique shows secondhand smoke damages lungs 2Health News:New method of drug delivery more effective at reaching brain tumors 2Health News:Visage Imaging Expands Availability of Its Advanced Visualization Offering 2Health News:Visage Imaging Expands Availability of Its Advanced Visualization Offering 3
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (240 style). Indications: Wide scleral bed. Outside diameter 31.7 mm....
Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Massive retinal breaks. Inner diameter: 26 mm....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Medicine Products: